Health
STAT+: A closer look at ProMis Neurosciences and its Alzheimer’s drug
Adam Feuerstein·STAT News·November 5, 2026

Shares of ProMis Neurosciences, developer of a treatment for Alzheimer’s disease, sold off sharply last week. A closer look at the reason why — and whether it holds up.
Read the full story at STAT News →